化疗联合树突状细胞疫苗和细胞因子诱导的杀伤细胞治疗结直肠癌：一项荟萃分析。
Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis.
作者信息
Zhou Xiuling, Mo Xiangqiong, Qiu Junlan, Zhao Jingjing, Wang Shuncong, Zhou Cuiling, Su Yonghui, Lin Zhong, Ma Haiqing
机构信息
Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China,
Department of General Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China.
出版信息
Cancer Manag Res. 2018 Nov 5;10:5363-5372. doi: 10.2147/CMAR.S173201. eCollection 2018.
AIM
To investigate the efficacy and safety of dendritic cell (DC) vaccine combined with cytokine-induced killer (CIK) cell therapy in colorectal carcinoma (CRC).
PATIENTS AND METHODS
PubMed, Embase, and Cochrane Library databases were searched systematically for clinical trials of DC vaccine and CIK cell therapy combined with chemotherapy for CRC. The primary and secondary endpoints were overall survival (OS) and disease-free survival (DFS), respectively. Pooled risk ratios were used to assess the treatment efficacy. Both random and fixed effects models were used for statistical analysis. The study population consisted of 871 CRC patients enrolled in four trials.
RESULTS
OS and DFS were significantly improved in patients who received chemotherapy combined with DC vaccine and CIK cells, and no severe adverse events were shown.
CONCLUSIONS
The study demonstrated that the addition of DC vaccine and CIK cell therapy to chemotherapy is feasible and effective in patients with CRC.
目的
探讨树突状细胞（DC）疫苗联合细胞因子诱导的杀伤细胞（CIK）治疗在结直肠癌（CRC）中的疗效和安全性。
患者和方法
系统检索PubMed、Embase和Cochrane图书馆数据库中DC疫苗和CIK细胞治疗联合化疗用于CRC的临床试验。主要和次要终点分别为总生存期（OS）和无病生存期（DFS）。采用合并风险比评估治疗效果。随机效应模型和固定效应模型均用于统计分析。研究人群包括四项试验中纳入的871例CRC患者。
结果
接受化疗联合DC疫苗和CIK细胞治疗的患者的OS和DFS显著改善，且未出现严重不良事件。
结论
该研究表明，在CRC患者中，化疗联合DC疫苗和CIK细胞治疗是可行且有效的。
Zotero 插件